Darmerica

Florida-based wholesale distributor and repackager of pharmaceutical ingredients, including peptide APIs, for compounding pharmacies and research. FDA inspected its Davie facility in March 2025 and issued a warning letter in December 2025 citing CGMP violations, distribution of retatrutide and other unapproved peptide APIs, and GLP-1 APIs received labeled only as "custom peptide".

Directory assessment: Darmerica is listed as a wholesaler in the peptide supply chain, serving North America markets from USA (FL). This supplier operates as a reseller or distributor, sourcing products from upstream manufacturers rather than running its own synthesis. This profile lists 1 source for reference. This supplier has a low confidence score because of the open FDA action recorded on this page — check its current FDA status before any transaction.